+

WO1997043247A1 - Inhibition de metalloproteases matricielles par des composes de phenetyle substitues - Google Patents

Inhibition de metalloproteases matricielles par des composes de phenetyle substitues Download PDF

Info

Publication number
WO1997043247A1
WO1997043247A1 PCT/US1997/007919 US9707919W WO9743247A1 WO 1997043247 A1 WO1997043247 A1 WO 1997043247A1 US 9707919 W US9707919 W US 9707919W WO 9743247 A1 WO9743247 A1 WO 9743247A1
Authority
WO
WIPO (PCT)
Prior art keywords
die
compounds
mmp
compound
carbons
Prior art date
Application number
PCT/US1997/007919
Other languages
English (en)
Inventor
Donald J. Wolanin
Original Assignee
Bayer Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corporation filed Critical Bayer Corporation
Priority to DK97923621T priority Critical patent/DK0907632T3/da
Priority to BR9709084A priority patent/BR9709084A/pt
Priority to DE69717811T priority patent/DE69717811T2/de
Priority to AU29385/97A priority patent/AU727899B2/en
Priority to CA002253870A priority patent/CA2253870C/fr
Priority to JP54097997A priority patent/JP3305328B2/ja
Priority to AT97923621T priority patent/ATE229497T1/de
Priority to EP97923621A priority patent/EP0907632B1/fr
Publication of WO1997043247A1 publication Critical patent/WO1997043247A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/16—Preparation of halogenated hydrocarbons by replacement by halogens of hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids

Definitions

  • This invention relates to enzyme inhibitors, and more particularly, to novel substituted phenethyl compounds or derivatives thereof useful for inhibiting matrix metalloproteases.
  • the matrix metalloproteases (a.k.a. matrix metailoendo-proteinases or MMPs) are a family
  • MMP-1 interstitial collagenase
  • stromelysin a.k.a.. proteoglycanase, transin, or MMP-3
  • gelatinase A a.k.a.. 72kDa-gelatinase or MMP-2
  • gelatinase B a.k.a.. 5kDa-gelatinase or MMP-9.
  • TIMPs tissue Inhibitor of MetalloEroteinase
  • MMPs are capable of destroying a variety of connective tissue components of articular cartilage or basement membranes.
  • Each MMP is secreted as an inactive proenzyme which must be cleaved in a subsequent step before it is able to exert its own proteolytic activity.
  • MMP-3 MMP-3
  • MMP-1 and MMP-9 MMP-1 and MMP-9
  • inhibitors should limit die activity of other MMPs that are not directly inhibited by such inhibitors.
  • MMP-3 can cleave and thereby inactivate the endogenous inhibitors of other proteinases such as elastase (Winyard. et al., FEBS Letts. 279, I, 91. 1991 ) Inhibitors of MMP-3 could thus influence the activity of other destructive proteinases by modifying the el of their endogenous inhibitors.
  • osteoarthritis Woessner, et al., J. Biol.Chem., 2J9_(6), 3633, 1984; Phadke. et al., J Rheumatoi 12, 852. 1983
  • rheumatoid arthritis Mullins, et al., Biochim. Biophys. ⁇ cta 6£5_, 1 17. 1983; Woolley, et al., Arthritis Rheum. 22, 1231 , 1977; Gravallese, et al.. Arthritis Rheum. 1076,
  • OA osteoarthritis
  • RA rheumatoid arthritis
  • septic arthritis the progressive loss of articular cartilage and thereby normal joint function.
  • nonsteroidal anti- iririamrnatory drugs SAIDs
  • SAIDs nonsteroidal anti- iririamrnatory drugs
  • Proteases are critical elements at several stages in the progression of metastatic cancer.
  • the proteolytic degradation of structural protein in the basal membrane allows for expansion of a tumor in the primary site, evasion from this site as well as homing and invasion in distant, secondary sites.
  • tumor induced angiogenesis is required for tumor growth and is dependent on proteolytic tissue remodeling.
  • Transfection experiments with various types of proteases have shown that the matrix metalloproteases play a dominant role in these processes in particular geiarinases A and B (MMP-2 and MMP-9, respectively).
  • geiarinases A and B geiarinases A and B (MMP-2 and MMP-9, respectively).
  • TIMP-2 a protein
  • TTMP-2 tumor-induced angiogenesis in experimental systems
  • EP 520573 Al The preferred compounds of these patents have peptide backbones with a zinc complexing group (hydroxamic acid, thiol, carboxylic acid or phosphinic acid) at one end and a variety of sidechains, bow those found in the natural amino acids as well as those with more novel functional groups.
  • a zinc complexing group hydroxamic acid, thiol, carboxylic acid or phosphinic acid
  • Such small peptides are often poorly absorbed, exhibiting low oral bioavailability. They are also subject to rapid proteolytic metabolism, thus having short half lives.
  • batimastat me compound described in Brown, et al., WO-9321942 A2
  • batimastat me compound described in Brown, et al., WO-9321942 A2
  • 3-biphenoylp ⁇ opanoic and 4-biaryioylbutanoic acids are described in the literature as anti-inflammatory, anti-platelet aggregation, anti-phlogistic, anti-proliferative, hypolipidemic, antirheumatic, analgesic, and hypocholesterolemic agents. In none of these examples is a reference made to MMP inhibition as a mechanism for the claimed therapeutic effect.
  • Certain related compounds are also used as intermediates in the preparation of liquid crystals. Specifically, Tomcufcik. et al.. US patent 3.784,701 claims certain substituted benzoylpropionic acids to treat inflammation and pain. These compounds include 3-biphenoylpropanoic acid (a.k.a. fenbufen) shown below.
  • Child, et al., J Pharm. Sci., ££, 466, 1977 describes structure-activity relationships of several analogs of fenbufen. These include several compounds in which the biphenyl ring system is substituted or the propanoic acid portion is substituted with phenyl, halogen, hydroxyl or methyl, or the carboxylic acid or carbonyl functions are converted to a variety of derivatives. No compounds are described which contain a 4'-substituted biphenyl and a substituted propanoic acid portion combined in one molecule. The phenyl (compounds XLDC and LXXVII) and methyl (compound XLVLT) substituted compounds shown below were described as inactive.
  • Nichl, et al. DE patent 1957750 also describes certain of the above mediylene substituted biphenoyipropanoic acids.
  • ⁇ -aroyl-acrylic acid epoxides including the following biphenyl compound. No compounds
  • Kitamura, et al., JP patent 60209539 describes certain biphenyl compounds used as intermediates for die production of liquid crystals including the following. The biphenyl is not substituted in these intermediates.
  • R 1 is an alkyl of 1-10 carbons.
  • Thyes, et al., DE patent 2854475 uses d e following compound as an intermediate.
  • the biphenyl group is not substituted.
  • R 1 , R 2 alkyl, benzyl, H, or, together with die nitrogen, morphoiinyl.
  • MMP-2 gelatinase
  • collagenase Durette, et al., WO-9529689
  • MMP inhibitors % The development of efficacious MMP inhibitors would afford new therapies for diseases mediated by die presence of. or an excess of MMP activity, including osteoarthritis, rheumatoid arthritis, septic arthritis, tumor metastasis, periodontal diseases, comeal ulcerations, and proteinuna.
  • MMPs Several inhibitors of MMPs have been described in the literature, including U iols (Beszant, et al.. J Med. Chem. 3_£, 4030, 1993), hydroxamic acids (Wahl, et al. Bioorg. Med. Chem. Lett. 5_ 349, 1995; Conway, et al.J. Exp. Med. 132, 449, 1995; Porter, et al., Bioorg.
  • This invention provides compounds having rnarrix metalloprotease inhibitory activity. These compounds are useful for inhibiting matrix metalloproteases and, ti erefore, combating conditions to which MMP's contribute. Accordingly, d e present invention also provides pharmaceutical compositions and methods for treating such conditions.
  • the compounds described relate to a method of treating a human to achieve an effect in which die effect is: alleviation of osteoarthritis. rheumatoid arthritis, septic arthritis, periodontal disease, comeal ulcerauon. protemu ⁇ a. aneurysmortic disease, dystrophic epidermolysis buliosa.
  • the compounds of the invention are also useful for birth control.
  • the method according to d e invention comprises administering an amount of a compound or composition of die invention as descnbed above, and in more detail in die detailed description below, which is effective to inhibit the activity of at least one matrix metalloprotease, resulting in achievement of die desired effect.
  • the compounds of die present invention are also useful scientific research tools for studying functions and mechanisms of action of matrix metalloproteases in botii in vivo and in vitro systems. Because of their MMP-inhibiting activity, the present compounds can be used to modulate MMP action, thereby allowing die researcher to observe die effects of reduced MMP activity in the experimental biological system under study.
  • This invention relates to compounds having matrix metalloprotease inhibitory activity and die generalized formula:
  • (T),A represents a substituted or unsubstituted aromatic 6-membered ring or heteroaromatic 5 • 6 membered ring containing 1 - 2 atoms of N, O, or S.
  • T represents one or more substituent groups, d e subscript x represents d e number of such substituent groups, and A represents d e aromatic or heteroaromatic ring, designated as d e A ring
  • the substituent group(s) T are independently selected from d e group consisting of halogen: alkyl; haloalkyl: alkenyl; alkynyl, benzyloxy, aikyloxy; -(CH ; ) P Q in which p is 0 or an integer of I - 4; and -alkenyl-Q in which the alkenyl moiety comprises 2 - 4 carbons.
  • Q in d e latter two groups is selected from the group consisting of aryl, heteroaryl, -CN, -CHO, -NO : , -COR 2 , -OCOR 2 .
  • R 2 represents H.
  • R 3 represents alkyl, aryl, heteroaryl, arylalkyl, or heteroaryl-alkyl
  • R* represents H, alkyl, aryl, heteroaryl, arylalkyl, heteroaryl-alkyl, alkenyl, alkynyl, haloalkyl, acyl, or alkyleneoxy or polyaikyleneoxy terminated widi H, alkyl, or phenyl.
  • Unsaturation in a moiety which is attached to Q or which is part of Q is separated from any N, O, or S of Q by at least one carbon atom.
  • the A ring may be unsubstituted or may carry up to 2 substiruents T. Accordingly, die subscript x is 0, 1, or 2.
  • B represents an aromatic 6-membered ring or a heteroaromatic 5 - 6 membered ring containing 1 • 2 atoms of N, O, or S. It is referred to as the B ring or B unit. When N is employed in conjunction with either S or O in die B ring, these heteroatoms are separated by at least one carbon atom.
  • D represents
  • r is 0-2, z is 1-4, Y l is H or CH 3 , and Y : is an alkyl of 3-6 carbons, a primary or secondary aminoalkyl of 3-6 carbons, a carboxylic acid of 2-5 carbons, a (l-mo ⁇ holinyl)alkyl wherein the alkyl group is 0-5 carbons, an ester of 3-5 carbons, a ketone of 3-5 carbons, or a arylalkyl wherein the alkyl group is 3-5 carbons; or Y 1 and Y 2 togetiier with die nitrogen atom to which they are attached form a 1 -piperidinyl or 1-mo ⁇ holinyl ring.
  • D and G as used in the above structure represent die D and G units of d e general formula (L) and are not part of die E unit; tiiey are included merely to indicate how die D, E and G groups are linked.
  • G represents -POjH, -M
  • M represents -COjH, -CONflt" ! or -CO j
  • R 12 represents alkyl of 1 - 4 carbons
  • R 13 represents any of the side chains of d e 19 noncyciic naturally occurring amino acids.
  • MMP inhibitory activity contain a substituent of significant size on d e propanoic or butanoic portion of die molecule.
  • the biphenyl portions of die best MMP inhibitors also preferably contain a substituent on die 4'-position, although when die propanoic or butanoic portions are optimally substituted, die unsubstituted biphenyl compounds of die invention have sufficient activity to be considered realistic drug candidates.
  • This invention provides compounds having matrix metalloprotease inhibitory activity.
  • d e present invention also provides pharmaceutical compositions and me ⁇ ods for treating such conditions.
  • the compounds described relate to a method of treating a human to achieve an effect in which die effect is: alleviation of osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, comeal uiceration, proteinuria, aneurysmortic disease, dystrophic epidermolysis buliosa, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibular joint disease, or demyelinaung diseases of die nervous system: tumor metastasis and degenerative cartilage loss following traumatic joint injury; and reduction of coronary thrombosis from adierosclerotic plaque rupture.
  • the compounds of the invention are also useful for birth control The method according to die ⁇ n ennon comp ⁇ ses administering an amount of a compound or composition
  • the compounds of die present invention are also useful scientific research tools for studying funcnons and mechanisms of action of matrix metalloproteases in both in vivo and m vitro systems. Because of their MMP-mhibiting activity, d e present compounds can be used to modulate MMP action, thereby allowing the researcher to observe the effects of reduced MMP acuvity in d e experimental biological system under study.
  • the compounds of die present invennon are materials having matrix metalloprotease inhibitory activity and die generalized formula
  • R 1 represents H or alkyl of 1 - 3 carbons.
  • an open bond indicates the point at which d e structure joins to anodier group.
  • die aromatic ring is referred to as die A ring or A unit and each T represents a substituent group, referred to as a T group or T unit
  • Substituent groups T are independently selected from die group consisting of: die halogens -F, -Cl, -Br, and -I; alkyl of 1 - 10 carbons; haloalkyl of 1 - 10 carbons; alkenyl of 2 - 10 carbons; alkynyl of 2 - 10 carbons; benzyloxy, aikyloxy of 1-5 carbons; - ⁇ CHjJ p Q in which p is 0 or an integer 1 - 4, and -alkenyl-Q in which the alkenyl moiety comprises 2 - 4 carbons.
  • Q in each of die latter two groups is selected from die group consisting of aryl of 6 - 10 carbons; heteroaryl comprising 4 • 9 carbons and at least one N, O, or S heteroatom, -CN, -CHO, -NO 2 , -CO,R 2 , -OCOR 2 , -SOR ⁇ -SO,R ⁇ -CON(R -SO j N R 2 ): , -C(O)R 2 ,
  • the groups R 2 , R ⁇ and R 4 are defined as follows.
  • R represents H; alkyl of 1 - 6 carbons: aryl of 6 - 10 carbons; heteroaryl comprising 4 - 9 carbons and at least one N, 0, or S heteroatom; arylalkyl in which die aryl portion contains 6 - 10 carbons and die alkyl portion contains 1 - 4 carbons; or heteroaryl-alkyl in which die heteroaryl portion comprises 4 - 9 carbons and at least one N. O, or S heteroatom and die alkyl portion contains 1 - 4 carbons.
  • R J represents alkyl of 1 - 4 carbons; aryl of 6 - 10 carbons; heteroaryl comprising 4 - 9 carbons and at least one N, O, or S heteroatom; arylalkyl in which die aryl portion contains 6 - 10 carbons and the alkyl portion contains 1 - 4 carbons; or heteroaryl-alkyl in which die heteroaryl portion comprises 4 - 9 carbons and at least one N, O, or S heteroatom and die alkyl portion contains 1 - 4 carbons.
  • R* represents H; alkyl of 1 - 12 carbons; aryl of 6 - 10 carbons; heteroaryl comprising 4 - 9 carbons and at least one N, O. or S heteroatom; arylalkyl in which d e aryl portion contains 6 - 10 carbons and die alkyl portion contains 1 - 4 carbons; heteroaryl-alkyl in which die heteroaryl portion comprises 4 - 9 carbons and at least one N, O, or S heteroatom and die alkyl portion contains 1 - 4 carbons; alkenyl of 2 - 12 carbons; alkynyl of 2 - 12 carbons; -(C q H ⁇ O-R 5 in which q is 1 -3, r is 1
  • R 5 is H provided q is greater tiian 1 , or R ⁇ is alkyl of 1 - 4 carbons, or phenyl; -(CH 2 ),X in which s is 2 - 3 and X is halogen; or -C(O)R 2 .
  • Any unsaturation in a moiety which is attached to Q or which is part of Q is separated from any N, O, or S of Q by at least one carbon atom, and die number of substituents, designated x, is 0.
  • the substituent group T can also be an acetylene containing moiety with the general formula:
  • n 1-4 and R 30 is selected from the group consisting of: HO-, MeO-. (n-Pr) ; N-. CH,CO : -. CH,CO : OCOj-, HO,C-, HOC-, Ph-, 3-OH-Ph-. and PhCH : 0-. provided that when R w is Ph or 3- OH-Ph. n - 0.
  • the B ring of generalized formula (L) is a substituted or unsubstituted aromatic or heteroaromatic ring, in which any substituents are groups which do not cause d e molecule to fail to t t die active site of die target enzyme, or disrupt the relative conformations of die A and B rings, such that they would be detrimental.
  • groups may be moieties such as lower alkyl, lower alkoxy, CN, NO ; , halogen, etc., but are not to be limited to such groups.
  • B represents an aromatic or heteroaromatic ring selected from die group consisting of:
  • R 1 is defined as above.
  • These rings are referred to as die B ring or B unit
  • R 15 may be a straight or cyclic alkyl group of 6- 12 carbons atoms, preferably of 7- 1 1 carbon atoms, and optionally may bear one or more pharmaceutically acceptable substituents which are discussed more fully below. Any branching or substitution is preferably located at least three chain atoms away from die point of attachment of die R" group to die phenyl ring.
  • R" may also be a polyedier of die formula R J2 O(C 2 H 4 O) h in which die subscript "h" is 1 or 2, and die group R 32 is a straight branched or cyclic alkyl group of 1-5 carbon atoms, preferably of 1 -3 carbon atoms and straight or phenyl, or benzyl.
  • R" optionally may bear one or more pharmaceutically-acceptable substituents which are discussed more fully below. Any branching or substitution is preferably located at least tiiree chain atoms away from die point of attachment of die polyedier R 15 group to die phenyl ring.
  • R l ⁇ may also be a substituted alkynyl group of die formula:
  • die subscript "b” is I -10 and die group R 3 is H-, HO- or R 34 ⁇ - and die group is preferably d e HO- group.
  • R 34 may be an alkyl group of 1-3 carbon atoms, or phenyl or benzyl.
  • R 33 optionally may bear one or more pharmaceutically-acceptable substituents which are discussed more fully
  • x is 0-4.
  • D represents the moieties:
  • r is 0-2, z is 1 -4, Y 1 is H or CH 3 , and Y 2 is an alkyl of 3-6 carbons, a primary or secondary aminoalkyl of 3-6 carbons, a carboxylic acid of 2-5 carbons, a (l-mo ⁇ holinyl)alkyl wherein die alkyl group is 0-5 carbons, an ester of 3-5 carbons, a ketone of 3-5 carbons, or a arylalkyl wherein the alkyl group is 3-5 carbons; or Y 1 and Y 2 togedier with die nitrogen atom to which diey are attached form a 1-piperidinyl or 1-mo ⁇ holinyi ring.
  • D and G as used in die above structure represent the D and G units of die general formula (L) and are not part of he E unit; d ey are included merely to indicate how die D, E and G groups are linked.
  • r 0 die structure above takes d e form:
  • the alkyl moiety includes a cyclobutyl ring and when r - 3 die alkyl moiery includes a cyclopentyl ring.
  • aryl or heteroaryl portions of any of the T groups optionally may bear up to two substituents selected from the group consisting of -(CH,) v C(R")(R ⁇ : )OH, - ⁇ CH : ) v OR".
  • -(CH,) v S(O)R -(CH,) y S(O),R
  • -(CH : ) y SO 2 N(R") : , -(CH ⁇ R 11 ),.
  • -(CH : ) v N(R M )COR : .
  • -OC(R") 0- in which both oxygen atoms are connected to d e aryl ring, -(CH )C v OR".
  • - ⁇ CH : ) y CON(R") , -(CH,) y CO : R", -(CH ⁇ OCOR 11 -halogen, -CHO, -CF trench -NO,, -CN. and -R . in which y is 0 - 4; R" represents H or alkyl of 1 - 4 carbons; and R' 2 represents alkyl of 1 - 4 carbons.
  • G represents -P0 3 H, -M
  • M represents -CO 2 H, -CONfll",, or -CO 2 R 12 , and R 13 represents any of die side chains of die 19 noncyclic naturally occurring amino acids.
  • Pharmaceutically acceptable salts of the compounds falling within die generalized formula (L) are also witi ⁇ n die invention. In d e compounds of die invention, die following are preferred.
  • the substituent group T is preferably halogen (most preferably Cl),
  • the subscr umber of T substituents is preferably 1 or 2, most preferably 1 , and tiiis substituent is on d e 4- position of ring A.
  • the A ring is preferably a phenyl or thiophene ring, most preferably phenyl.
  • the B ring is preferably a 1,4-phenylene or 2,5-thiophene ring, most preferably 1,4-phenylene.
  • the D unit is most preferably a carbonyi group.
  • the E unit is preferably:
  • D and G are the D and G units and are not part of E, z is 1-4 (most preferably 2) and R 24 is one of die following
  • the G unit is most preferably a carboxylic acid group.
  • alkyl means straight branched, cyclic, and polycyclic materials.
  • haloalkyl means partially or fully halogenated alkyl groups such as -(CH j ⁇ Cl, -CFjand -C ⁇ F,,. for example.
  • the invention relates to compounds of generalized formula (L) in which at least one of the units A, B, T, and E comprises a heteroaromatic ring. Preferred
  • ⁇ heteroaromatic ⁇ ng-containing compounds are ose in which the heteroaryl groups are heteroar of 4 - 9 carbons comprising a 5 - 6 membered heteroaromatic ⁇ ng containing O. S, or NR 1 when the ⁇ ng is 5 -membered, and N when said ⁇ ng is 6-membered.
  • Particularly preferred heteroaromatic ring-containing compounds are those in which at least one of the A and B units comp ⁇ ses a thiophene nng.
  • the A umt is duophene. it is preferably connected to B umt at position 2 and carries one substituent group T on position 5.
  • B Unit duophene, it is preferably connected through positions 2 and 5 to D and A units respectively.
  • d e A and B ⁇ ngs are preferably phenyl and phenylene. respectively, the A ring preferably bears at least one substituent group T preferably located on the position furthest from die position of d e A ⁇ ng which is connected to d e B ⁇ ng, the D umt is preferably a carbonyl group, and die G umt is preferably a carboxyl group.
  • one substituent group T is located on die 4- position of die A ring, relative to the point of attachment between die A and B rings, n ⁇ 1 -5 and R 24 is ortho, let or para to die
  • Substituent group T of iis subset is preferably a halogen.
  • T is most preferably Cl and is in the para position of die A ring relative to die B ring.
  • the invention also relates to certain intermediates useful in die syndiesis of some of the claimed inhibitors. These intermediates are compounds having die generalized formula:
  • R a ⁇ is a halogen and R 22 is H or an alkyl (preferably ethyl) or allylallcyl (wherein the alkyl is preferably memyl) group.
  • XVTJ 4 ' -chloro- «-[2-[4-(4-mo ⁇ holinylcarbonyl)phenyl]ed ⁇ yl]- ⁇ -oxo-[ 1,1 ' -biphenyl]-4-butanoic acid
  • XVuT 4'-cWcro- ⁇ [2-(4 ⁇ [(3-memylbutyl)arn o butanoic acid
  • the compounds of die invention may be prepared by use of known chemical reactions and procedures. Nevertheless, the following general preparative mediods are presented to aid d e reader in synthesizing die inhibitors, widi more detailed particular examples being presented below in die experimental section describing die working examples.
  • the salt forming ion derived from such bases can be metal ions, e.g., aluminum, alkali metal ions, such as sodium of potassium, alkaline earth metal ions such as calcium or magnesium, or an amine salt ion, of which a number are known for this purpose.
  • metal ions e.g., aluminum, alkali metal ions, such as sodium of potassium, alkaline earth metal ions such as calcium or magnesium, or an amine salt ion, of which a number are known for this purpose.
  • alkali metal ions such as sodium of potassium
  • alkaline earth metal ions such as calcium or magnesium
  • an amine salt ion of which a number are known for this purpose.
  • ammonium salts arylalkylamines such as
  • dibenzylamine and ⁇ hbenzyie ylenediamine lower alkylamines such as memyiamine, r-bu ⁇ yiamine, procaine, lower alkylpiperidines such as N-ethylpiperidine, cycloalkylamines such as cyclohexyiamine or dicyclohexylamine, 1 -adamantylamine, benzadiine, or salts derived from amino acids like arginine, lysine or die like.
  • the physiologically acceptable salts such as die sodium or potassium salts and die amino acid salts can be used medicinally as described below and are preferred.
  • salts are produced by reacting the acid form of the invention compound widi an equivalent of the base supplying die desired basic ion in a medium in which die salt precipitates or in aqueous medium and tiien lyophilizing.
  • the free acid form can be obtained from die salt by conventional neutralization techniques, e.g., with potassium bisulfate, hydrochloric acid, etc.
  • the compounds of die present invention have been found to inhibit die matrix metalloproteases MMP-3, MMP-9 and MMP-2, and to a lesser extent MMP-1 , and are tiierefore useful for treating or preventing die conditions referred to in he background section.
  • MMP-3, MMP-9 and MMP-2, and to a lesser extent MMP-1 are tiierefore useful for treating or preventing die conditions referred to in he background section.
  • tiiat compounds of the invention should also inhibit such otiier MMPs to varying degrees. Varying the substituents on die biaryl portions of die molecules, as well as diose of die propanoic or butanoic acid chains of d e claimed compounds, has been demonstrated to affect die relative inhibition of die listed MMPs.
  • compounds of this general class can be "tuned" by selecting speci ic substituents such tiiat inhibition of specific MMP(s) associated wid specific padioiogical conditions can be enhanced while leaving non-involved MMPs less affected.
  • the method of treating matrix metalloprotease-mediated conditions may be practiced in mammals, including humans, which exhibit such conditions.
  • the inhibitors of the present invention are contemplated for use tn vete ⁇ nary and human applications.
  • diey will be employed m pharmaceutical compositions containing active ⁇ ngred ⁇ ent(s) plus one or more pharmaceutically acceptable earners, diluents, fillers, binders, and other exciptents. depending on die administration mode and dosage form contemplated.
  • Administrauon of the inhibitors may be by any suitable mode known to those skilled in die art.
  • suitable parenteral administration include intravenous, intraarticular, subcutaneous and intramuscular routes.
  • Intravenous administration can be used to obtain acute regula ⁇ on of peak plasma concentrations of the drug. Improved half-life and targeting of the drug to die joint cavities may be aided by entrapment of the drug in liposomes. It may be possible to improve die selectivity
  • sustained drug release For improved convenience of die dosage form it may be possible to use an i p. implanted reservoir and septum such as die Percuseal system available from Pharmacia. Improved convenience and patient compliance may also be achieved by die use of eitiier injector pens (e.g. the Novo Pin or Q-pen) or needle-free jet injectors (e.g. from Bioject Mediject or Becton Dickinson). Prolonged zero-order or other precisely controlled release such as pulsatile release can also be achieved as needed using implantable pumps with delivery of the drug dirough a carmula
  • Examples include the subcutaneously implanted osmotic pumps available from ALZA, such as d e ALZET osmotic pump.
  • Nasal delivery may be achieved by inco ⁇ oration of the drug into bioadhesive paniculate carriers ( ⁇ 200 -*m) such as those comprising cellulose, polyacrylate or polycarbophil. in conjunction with s Desible abso ⁇ tion enhancers such as phospholipids or acylcamitines. Available systems include those developed by DanBiosys and Scios Nova.
  • Oral delivery may be achieved by inco ⁇ oration of the drug into tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions. Oral delivery may also be achieved by incorporation of die drug into enteric coated capsules designed to release die drug into die colon where digestive protease activity is low. Examples include the OROS-CT/OsmetTM and PULSINCAPTM systems from ALZA and Scherer Drug Delivery Systems respectively. Otiier systems use azo-crosslinked polymers tiiat are degraded by colon specific bacterial azoreductases, or pH sensitive polyacrylate polymers that are activated by die rise in pH at d e colon. The above systems may be used in conjunction widi a
  • Rectal delivery may be achieved by incorporation of the drug into suppositories.
  • the compounds of diis invention can be manufactured into die above listed formulations by the addition of various dierapeuticaliy inert inorganic or organic carriers well known to those
  • tiiese include, but are not limited to, lactose, com starch or
  • t p derivatives thereof talc, vegetable oils, waxes, fats, polyols such as polyethylene glycol. water. saccharose, alcohols, glycerin and the like.
  • Various preservatives, emulsifiers, dispersants. tlavorants, wetting agents, antioxidants, sweeteners, colorants, stabilizers, salts, buffers and the iike are also added, as required to assist in die stabilization of the formulation or to assist in increasing bioavailability of the active ingredient(s) or to yield a formulation of acceptable flavor or odor in the case of oral dosing.
  • die pharmaceutical composition to be employed will depend on the recipient and the condition being treated. The requisite amount may be determined widiout undue experimentation by protocols known to diose skilled in die art. Alternatively, die requisite amount may be calculated, based on a determination of the amount of target enzyme which must be inhibited in order to treat die condition.
  • the matrix metalloprotease inhibitors of die invention are useful not only for treatment of the physiological conditions discussed above, but are also useful in such activities as purification of metalloproteases and testing for matrix metalloprotease activity.
  • activity testing can be botii in vitro us g natural or synthetic enzyme preparations or in vivo using, for example, animal models in which abnormal destructive enzyme levels are found spontaneously (use of genetically mutated or transgenic animals) or are induced by administration of exogenous agents or by surgery which disrupts joint stability.
  • Analytical thin-layer chromatography was performed on Anaitech' pre-coated glass-backed silica gel GHLF 250 mm plates. Visualization of spots was effected by one of die following techniques: (a) ultraviolet illumination, (b) exposure to iodine vapor, (c) immersion of die plate in a 10% solution of phosphomolybdic acid in edianol followed by heating, and (d) immersion of die plate in a 3% solution of p-anisaldehyde in edianol containing 0.5% concentrated sulfuric acid followed by heating.
  • TLC thin-layer chromatography
  • Mass spectral (MS) data were obtained on a Kratos Concept l-H spectrometer by liquid-cesium secondary ion (LCIMS), an updated version of fast atom bombardment (FAB). Most of d e compounds sysdiesized in the experiments below were analyzed by mass spectroscopy, and the spectra were consistent widi the proposed structures in each case.
  • LIMS liquid-cesium secondary ion
  • FAB fast atom bombardment
  • Step 1 A solution of o-iodophenylacetic acid ( 19.87 g, 75.83 mmol) in dry tetrahydrofuran (110 mL) was added dropwise over 41 min to a solution of borane in tetrahydrofuran (151 mL of 1 M solution, ca. 151.0 mmoi) which was cooled widi an ice-water bath. The reaction was stirred at 0
  • Neat 2-(2-iodophenyl)ed ⁇ anol 17.75 g, 71.55 mmol was treated dropwise widi phosphorous tribromide (3.5 mL, 36.85 mmol) over 6 min while the reaction vessel was placed in a water bath to modulate die exotiiermic reaction. Stirring was continued for 15 min at room temperature and then for 2 h while the mixture was heated in an oil batii at 100 'C. The reaction was cooled to room temperature, diluted with ether and quenched carefully widi water (frotiiing/exotherm!). The layers were separated, d e organics were washed with saturated sodium bicarbonate and dried (Na 2 SO « ).
  • Step 2 A dry, 250 mL, round-bottomed flask was equipped widi a stir bar and an argon inlet. The flask was charged widi a suspension of sodium hydride (1.65 g of 95% NaH; -65.1 mmol) in dry THF (25 mL). Diethyi malonate (9.99 g, 62.37 mmol) was added dropwise via syringe over 25 min.
  • Step 3 A 2-L, diree-necked, round-bottomed flask was equipped widi a mechanical stirrer, a
  • Step 4 A dry, 250 mL, round-bottomed flask was equipped widi a stir bar and an argon inlet. The flask was charged with a suspension of sodium hydride (1.07 g of 95% NaH; -42.4 mmol) in dry THF ( 100 mL) and was cooled with an ice-water badi. A solution of the malonate from Step 2
  • Step 5 The diacid product from step 4 (22.06 g) was dissolved in 1 ,4-dioxane (400 mL) and was held at reflux under argon overnight. Concentration gave d e crude product as a yellow solid (19.50 g) which was recrystallized from chloroform to deliver two crops of die title compound Example 1 as a fluffy solid (11.55 g, 22.26 mmol; 7% overall yield) after overnight drying in a vacuum oven at 66 ' C. TLC (chloroform-medianol, 20: 1 with trace amount of acetic acid): R_- s 0.54.
  • Step 6 A portion of the acid from Step 5 (405.7 mg, 0.78 mmol) was dissolved in climediylsuLfbxide (3.0 mL). Trieuryl amine (0.34 mL) was added followed by palladium (IT) aceute (20.3 mg, 0.09 mmol), l,3-bis(diphenylphosphino)propane (35.2 mg, 0.085 mmoi) and phenethylamine (1.42 g, 11.7 mmol). Carbon monoxide was bubbled dirough die solution for five minutes. The solution was placed under a carbon monoxide atmosphere and was heated in an oil
  • Table I The examples in Table I were prepared by d e palladium-mediated carbonylation metiiod of Example I widi die appropriate amine in place of phenediyl amine. Furthermore, die requisite isomeric iodide precursors were prepared by the metiiod of Example 1 using m- or p-iodophenylacetic acid as starting material.
  • Example 8 The acid from Example 8 (180 mg, 0.34 mmol) was saponified according to die general metiiod of Example 22 to give the diacid product as a yellow solid (142 mg, 85% yield). MP 71-75 °C.
  • Step 1 A sample of die iodo acid from Example I, Step 5 (1.0 g, 1.93 mmol) was suspended in dry dichloromediane (20 mL). To d e stirred suspension was added benzyl alcohol (0.44 mL, 4.05 mmol), DCC (0.6 g, 2.89 mmol) and DMAP (50 mg, 0.39 mmol). The yellow suspension was stirred overnight at room temperature. The mixture was diluted wid hexanes (60 mL) and water (5 mL). The mixture was stirred and filtered and d e filter cake was washed wid hexanes. The organics were separated, dried (MgSO «) and concentrated to an oil. Flash chromatography (gradient
  • Step 2 The iodo ester from Step 1 (0.910 g, 1.49 mmol) was subjected to the palladium-mediated carbonylation metiiod of Example 1 widi water in place of phenediyl amine to give the half acid ester product (475 mg, 0.90 mmol; 61% yield). MS (FAB-LSDMS) 527TM+H] *
  • Step 3 The half acid ester from Step 2 (0.46 g, 0.87 mmol) was dissolved in dichlorometiiane (8 mL). To the solution was added 4- ⁇ 2-aminoethyl)mo ⁇ holine (0.13 g, 0.96 mmol) and l-hydroxybenzotriazole (0.12 g, 0.87 mmol). The flask was washed down widi dichloromethane (2 mL) and cooled in an ice bath.
  • Step 1 The meta-iodo isomer of Example 1 , Step 5 (i.e., prepared according to die procedure of
  • Example 1 beginning widi -iodophenyl acetic acid; 2.0 g, 3.86 mmol) was dissolved in 1,2- dichloroediane (8 mL). To die solution was added edianol (0.68 mL, 11.57 mmol) and several drops of concenrrated sulfuric acid. The solution was held at reflux overnight The mixture was cooled, loaded onto a silica column and flash chromatographed (hexanes-ediyl acetate, 3:1) to give he product as a yellow oil (2.142 g) which retained solvent by proton NMR.
  • TLC hexanes-ediyl acetate
  • Step 2 The iodo ester from Step 1 (2.1 g, 3.84 mmol) was subjected to the palladium-mediated carbonylation method of Example I with water in place of phenediyl amine to give d e half acid ester product ( 1.1 g, 2.37 mmol; 62% yield).
  • Table II The examples in Table II were prepared by die general multi-step metiiod of Example 25 starting widi die appropriate iodo acid and amine precursors.
  • Step 1 A one-necked, 1000-mL, round-bottomed flask equipped widi an argon inlet adapter was charged with 500 mL CH,C1 suitcase 4-phenylphenol acetate (50.0 g, 235 mmol), bromoaceryl bromide (73.2 g, 31.6 mL, 363 mmol) and cooled to 0 ⁇ C while aluminum trichloride (94.2 g, 707 mmol) was added in small portions ca. over 5 min. The resulting mixture was stirred for 30 min at 0 °C and 12 h at room temperature.
  • reaction mixture was added to a cold 10% HCl solution (500 mL), and extracted tiiree times with 200-mL portions of ediyl acetate.
  • the organic phase was dried over MgSO , filtered, and concentrated to provide a black solid. Recrystallization from ethyl
  • Step 2 The desired compound was synthesized from the product of Step 1 above by the general procedure in Example I .
  • TLC hexanes - ediyl acetate, 3 : 1
  • R / 0.49.
  • Step 3 A tetrahydrofuran (400 mL) and ethanol (50 mL) solution of die product from Step 2 ( 18.4 g) was treated with . 2 C0 3 and stirred under argon at room temperature overnight. Because a significant amount of starting material remained, die volume of die reaction was reduced by one half and additional K 2 CO, (12 g) was added. The reaction was complete after 3 h. The reaction was concentrated and acidified with 10% HCl. The product was extracted with ediyl acetate, dried (Na,SOJ and concentrated to a brown oily residue. Purification by flash chromatography (hexanes - ediyl acetate, 3: 1) gave die product as a yellow oil (14.8 g; 86%). TLC (hexanes - ethyl acetate,
  • Example 30 was prepared by the palladium-mediated carbonylation mediod of Example 1 widi piperidine as the nucleophile. MP 100-102.5 °C.
  • Example 31 was prepared by die general procedure of Example 30 using iodopeniane in die alkylation step and piperidine as the nucleophile in the palladium-mediated carbonylation. MP 105.5-107.5 a C.
  • Example 32 was prepared by die general procedure of Example 30 using die appropriate isomeric iodo precursor. MP 168-169 °C.
  • the P218 quenched fluorescence assay (Microfluorometric Profiling Assay) is a modification of that originally described by Knight et al., FEBS Lett. 29£, 263, 1992 for a related substance and a variety of matrix metalloproteinases (MMPs) in cuvettes.
  • the assay was run widi each invention compound and the tiiree MMPs, Mmp-3, MMP-9 and MMP-2, analyzed in parallel, adapted as follows for a 96-well microtiter plate and a Hamilton AT* workstation.
  • P218 Fluorogenic Substrate is a synthetic substrate containing a 4-acetyl-7- methoxycoumarin (MCA) group in die N-terminal position and a 3-[2, 4-dinitrophenyi]-L-2,3- diaminopropionyi (DPA) group internally. This is a modification of a peptide reported by Knight ( 1992) dal was used as a substrate for matrix metalloproteinases.
  • MCA 4-acetyl-7- methoxycoumarin
  • DPA diaminopropionyi
  • Pro-MMP-2 Human pro-gelatinase A (pro-MMP-2) was prepared using a vaccinia expression system according to die method of Fridman, et al., J Biol. Chem. 26 , 15398, 1992.
  • Pro-MMP-2 at 252 mg/mL was diluted 1 :5 to a final concentration of 50 ⁇ g mL solution in 25 mM Tris at pH 7.5, 5 mM CaCl,, 150 mM NaCl, and
  • APMA acetate
  • 10 mM 3.5 mg/mL
  • APMA solution was added at 1/20 die reaction volume for a final AMPA concentration of 0.5 mM, and the enzyme was incubated at 37 °C for 30 mm.
  • Activated MMP-2 (15 mL) was dialyzed twice vs. 2 L of MMP-2 activation buffer (dialysis membranes were pre-treated with a solution consisting of 0.1% BSA in MMP-2 activation buffer for 1 min.. followed by extensive H 2 O washing). The enzyme was concentrated on Centric ⁇ n concentraton (concentrators were also pre-treated a solution consisting of 0.1% BSA in MMP -2 activation buffer for 1 min.. followed by washing with H 2 O, ⁇ en MMP-2 activation buffer) with re-dilution followed by re-concentration repeated twice. The enzyme was diluted to 7.5 mL (0.5
  • Pro-MMP-9 Human pro-gelatinase B (pro-MMP-9) derived from
  • Pro-MMP-9 activation buffer 50 mM Tris at pH 7.4, lOmM CaCU, 150 mM NaCl, and 0.005% Brij-35 (MMP-9 activation buffer) was activated by incubation widi 0.5 mM -aminophenylmercuric acetate (APMA) for 3.5 h at 37 °C. The enzyme was diaiyzed against the same buffer to remove die APMA. Instrumentation:
  • Hamiltion Microlab AT Plus The MMP-Profiling Assay is performed robotically on a Hamilton MicroLab AT Plus*.
  • the Hamilton is programmed to: (1) serially dilute up to 1 1 potential inhibitors automatically from a 2.5 mM stock in 100% DMSO; (2) distribute substrate followed by inhibitor into a 96 well Cytofluor plate; and (3) add a single enzyme to die plate with mixing to start d e reaction. Subsequent plates for each additional enzyme are prepared automatically by beginning the program at the substrate addition point, remixing d e diluted inhibitors and beginning die reaction by addition of enzyme. In this way, all MMP assays were done using die same inhibitor
  • Microfluorometric Reaction Buffer Dilution of test compounds, enzymes, and
  • P21 substrate for die microfluorometric assay were made in microfluorometric reaction buffer consisting of 50 mM 2-(N-mo holino)ethanesulfonic acid (MES) at pH 6.5 widi 10 mM CaCL, 150 mM NaCl. 0.005% Brij- 5 and 1% DMSO. eJtadj.:
  • MES 2-(N-mo holino)ethanesulfonic acid
  • MMP Microfluorometric Profiling Assay The assay is done with a final substrate concentration of 6 ⁇ M P218 and approximately .5 to .8 nM MMP widi variable drug concentrations.
  • the Hamilton is programmed to serially dilute up to 1 1 compounds from a 2.5 mM stock (100% DMSO) to lOx me final compounds concentrations in d e assay.
  • die instrument delivers various amounts of microfluoromentric reaction buffer (MRB) to a 96 tube rack of I ml Marsh dilution rubes.
  • MMP microfluoromentric reaction buffer
  • the instrument men picks up 20 ⁇ l of inhibitor (2.5 mM) from the sample rack and mixes it widi a buffer in row A of the Marsh rack, resulting in a 50 ⁇ M drug concentration. The inhibitors are then serially diluted to 10, 5, 1, .2, .05 and .01 ⁇ M. Position 1 on die sample rack contains only DMSO for the "enzyme-only" wells in the assay, which results in no inhibitor in column 1, rows A dirough H. The instrument men distributes 107 ⁇ l of P218 substrate (8.2 ⁇ M in MRB) to a single 96 well cytofluor microuter plate.
  • the instrument re-mixes and loads 14.5 ⁇ l of diluted compound from rows A to G in the Marsh rack to corresponding rows in die microuter plate.
  • Row H represents die "background” row and 39.5 ⁇ l of MRB is delivered in placed of drug or enzyme).
  • the reaction is started by adding 25 ⁇ l of the appropriate enzyme (at 5.86 times die final enzyme concentration) from a BSA treated reagent reservoir to each well, excluding Row H, die "background” row.
  • the enzyme reservoir is pretreated with 1% BSA in 50 mM Tris, pH 7.5 containing 150 mM NaCl for 1 hour at room temp., followed by extensive H : 0 washing and drying at room temp.).
  • the plate After addition and mixing of the enzyme, the plate is covered and incubated for 25 min. at 37°C. Additional enzymes are tested in die same manner by beginning the Hamilton program with the distribution of P218 substrate to die microtiter plate, followed by re-mixing and distribution of the drug from die same Marsh rack to die microtiter plate. The second (or third, etc.) MMP to be tested is then distributed from a reagent rack to the microtiter plate widi mixing, prior to covering and incubation. This is repeated for all additional MMP's to be tested.
  • IC50 and Ki Determination in Microfluorometric Assay Data generated on the Cytofluor TJ is copied from an exported ".CSV" file to a master Excel spreadsheet Data from several different MMPs (one 96 well plate per MMP) were calculated simultaneously. The percent inhibition is determination for each drug concentration by comparing die amount of hydrolysis (fluorescence units generated over 25 minutes of hydrolysis) of wells containing compound widi die "enzyme only" wells in column 1. Following subtraction of die background the percent inhibition was calculated as:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés inhibiteurs de métalloprotéases matricielles, leurs compositions pharmaceutiques et une méthode de traitement de maladies à l'aide de ces composés. Les composés de l'invention ont la formule (I) dans laquelle R25 représente une fraction phényléthyle substituée. Ces composés sont utiles pour inhiber des métalloprotéases matricielles et, par conséquent, combattre des états auxquels les métalloendo-protéinases matricielles (MMP) contribuent, tels que l'ostéo-arthrose, la polyarthrite rumatoïde, l'arthrite septique, les maladies périodontiques, l'ulcération de la cornée, la protéinurie, les maladies aortiques anévrismales, l'épidermolyse dystrophobique, les lésions bulleuses, des états conduisant à des réactions inflammatoires, des ostéopénies induites par l'activité des MMP, des maladies des articulations temporomendibulaires, des maladies démyélinisantes du système nerveux, la métastase de tumeurs ou la perte de cartilage dégénérative suite à des lésions articulaires traumatiques, et la thrombose coronaire résultant de la rupture des plaques athéroscléreuses. La présente invention concerne également des compositions pharmaceutiques et des méthodes de traitement de ces états.
PCT/US1997/007919 1996-05-15 1997-05-12 Inhibition de metalloproteases matricielles par des composes de phenetyle substitues WO1997043247A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DK97923621T DK0907632T3 (da) 1996-05-15 1997-05-12 Inhibering af matrixmetalloproteaser med substituerede phenethyl-forbindelser
BR9709084A BR9709084A (pt) 1996-05-15 1997-05-12 Composto de inibição de metaloproteinase de matriz composição tendo atividade de inibição de metaloprotease de matriz e processos para inibir a atividade de metaloprotease de matriz em um mamífero e para tratar mamíferos
DE69717811T DE69717811T2 (de) 1996-05-15 1997-05-12 Substituierte phenethyl-derivate als matrx-metalloprotease-inhibitoren
AU29385/97A AU727899B2 (en) 1996-05-15 1997-05-12 Inhibition of matrix metalloproteases by substituted phenalkyl compounds
CA002253870A CA2253870C (fr) 1996-05-15 1997-05-12 Inhibition de metalloproteases matricielles par des composes de phenetyle substitues
JP54097997A JP3305328B2 (ja) 1996-05-15 1997-05-12 置換フェンアルキル化合物によるマトリックスプロテアーゼの阻害
AT97923621T ATE229497T1 (de) 1996-05-15 1997-05-12 Substituierte phenethyl-derivate als matrx- metalloprotease-inhibitoren
EP97923621A EP0907632B1 (fr) 1996-05-15 1997-05-12 Inhibition de metalloproteases matricielles par des composes de phenetyle substitues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64502696A 1996-05-15 1996-05-15
US08/645,026 1996-05-15

Publications (1)

Publication Number Publication Date
WO1997043247A1 true WO1997043247A1 (fr) 1997-11-20

Family

ID=24587359

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/007919 WO1997043247A1 (fr) 1996-05-15 1997-05-12 Inhibition de metalloproteases matricielles par des composes de phenetyle substitues

Country Status (24)

Country Link
EP (1) EP0907632B1 (fr)
JP (1) JP3305328B2 (fr)
CN (1) CN1124255C (fr)
AR (1) AR007100A1 (fr)
AT (1) ATE229497T1 (fr)
AU (1) AU727899B2 (fr)
BR (1) BR9709084A (fr)
CA (1) CA2253870C (fr)
CO (1) CO5070565A1 (fr)
DE (1) DE69717811T2 (fr)
DK (1) DK0907632T3 (fr)
ES (1) ES2188943T3 (fr)
HN (1) HN1997000071A (fr)
HR (1) HRP970243B1 (fr)
ID (1) ID17424A (fr)
PA (1) PA8429801A1 (fr)
PE (1) PE66298A1 (fr)
PT (1) PT907632E (fr)
SV (1) SV1997000037A (fr)
TN (1) TNSN97082A1 (fr)
TW (1) TW363056B (fr)
WO (1) WO1997043247A1 (fr)
YU (1) YU18497A (fr)
ZA (1) ZA974029B (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061413A1 (fr) * 1998-05-27 1999-12-02 Bayer Corporation Derives d'acide 4-biarylbutyrique et 5-biarylpentanoique utilises comme inhibiteurs de metalloproteases matricielles
WO2000040539A1 (fr) * 1998-12-30 2000-07-13 Bayer Aktiengesellschaft Utilisation de derives d'acides 4-biarylbutyrique et 5-biarylpentanoique substitues, en tant qu'inhibiteurs de la metalloprotease matricielle, pour le traitement des maladies respiratoires
EP1031349A1 (fr) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Utilisation d'acides 4-biarylbutyriques et 5-biarylpentanoiques substitués pour traiter les maladies cérébrales
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
WO2015150350A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Acides cyclopentanecarboxyliques à disubstitution 2,5 pour traiter des maladies des voies respiratoires
WO2015150362A2 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Dérivés chiraux d'acide cyclopentanecarboxylique à disubstitution 2,5 et leur utilisation
WO2015150363A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Acides cyclopentanecarboxyliques à disubstitution 2,5 et leur utilisation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2901320B1 (fr) * 2006-05-17 2008-07-04 Univ Savoie Etablissement Publ Dispositif miniaturise apte a fonctionner comme moteur ou refroidisseur selon un cycle thermodynamique de stirling

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2112716A1 (de) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester
US3784701A (en) * 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
WO1996015096A1 (fr) * 1994-11-15 1996-05-23 Bayer Corporation Acides 4-biarylbutyrique ou 5-biarylpentanoique substitues et leurs derives en tant qu'inhibiteurs de metalloproteases matrices

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970242A2 (en) 1996-05-15 1998-04-30 Bayer Ag Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutric acids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784701A (en) * 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
DE2112716A1 (de) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester
WO1996015096A1 (fr) * 1994-11-15 1996-05-23 Bayer Corporation Acides 4-biarylbutyrique ou 5-biarylpentanoique substitues et leurs derives en tant qu'inhibiteurs de metalloproteases matrices

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHICCARELLI, F. S. ET AL: "Disposition and metabolism of fenbufen in several laboratory animals", ARZNEIM.-FORSCH. (1980), 30(4A), 707-15 CODEN: ARZNAD;ISSN: 0004-4172, 1980, XP002043281 *
CHILD, R. G. ET AL: "A new nonsteroidal antiinflammatory analgesic:.gamma.-oxo(1,1'- biphenyl)-4-butanoic acid (Fenbufen). Chemistry and activity of analogs", ARZNEIM.-FORSCH. (1980), 30(4A), 695-702 CODEN: ARZNAD;ISSN: 0004-4172, 1980, XP002043280 *
CHILD, RALPH G. ET AL: "Fenbufen, a new anti-inflammatory analgesic: synthesis and structure-activity relations of analogs", J. PHARM. SCI. (1977), 66(4), 466-76 CODEN: JPMSAE, 1977, XP000560277 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061413A1 (fr) * 1998-05-27 1999-12-02 Bayer Corporation Derives d'acide 4-biarylbutyrique et 5-biarylpentanoique utilises comme inhibiteurs de metalloproteases matricielles
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
WO2000040539A1 (fr) * 1998-12-30 2000-07-13 Bayer Aktiengesellschaft Utilisation de derives d'acides 4-biarylbutyrique et 5-biarylpentanoique substitues, en tant qu'inhibiteurs de la metalloprotease matricielle, pour le traitement des maladies respiratoires
US6900194B1 (en) 1998-12-30 2005-05-31 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
EP1031349A1 (fr) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Utilisation d'acides 4-biarylbutyriques et 5-biarylpentanoiques substitués pour traiter les maladies cérébrales
WO2000050017A3 (fr) * 1999-02-25 2001-02-01 Bayer Ag Utilisation de derives substitues d'acides 4-biarylbutyrique et 5-biarylpentanoique pour le traitement des maladies cerebrales
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
WO2015150350A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Acides cyclopentanecarboxyliques à disubstitution 2,5 pour traiter des maladies des voies respiratoires
WO2015150362A2 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Dérivés chiraux d'acide cyclopentanecarboxylique à disubstitution 2,5 et leur utilisation
WO2015150363A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Acides cyclopentanecarboxyliques à disubstitution 2,5 et leur utilisation

Also Published As

Publication number Publication date
TNSN97082A1 (fr) 2005-03-15
JPH11510517A (ja) 1999-09-14
BR9709084A (pt) 1999-08-03
PA8429801A1 (es) 2000-05-24
JP3305328B2 (ja) 2002-07-22
CA2253870A1 (fr) 1997-11-20
HRP970243B1 (en) 2002-06-30
AU727899B2 (en) 2001-01-04
CO5070565A1 (es) 2001-08-28
ZA974029B (en) 1998-02-19
EP0907632B1 (fr) 2002-12-11
DE69717811T2 (de) 2003-05-28
ATE229497T1 (de) 2002-12-15
ID17424A (id) 1997-12-24
CN1225624A (zh) 1999-08-11
CA2253870C (fr) 2004-01-06
ES2188943T3 (es) 2003-07-01
DK0907632T3 (da) 2003-04-07
CN1124255C (zh) 2003-10-15
PT907632E (pt) 2003-04-30
AU2938597A (en) 1997-12-05
EP0907632A1 (fr) 1999-04-14
AR007100A1 (es) 1999-10-13
PE66298A1 (es) 1998-10-23
SV1997000037A (es) 1999-01-14
TW363056B (en) 1999-07-01
DE69717811D1 (en) 2003-01-23
YU18497A (en) 1999-11-22
HRP970243A2 (en) 1998-04-30
HN1997000071A (es) 1997-06-18

Similar Documents

Publication Publication Date Title
US6500847B2 (en) Inhibition of matrix metalloproteases by substitued biaryl oxobutyric acids
AU714207B2 (en) Inhibition of matrix metalloproteases by 2-substituted-4- (4-substitutedphenyl)-4-oxobutyric acids
WO1997043239A9 (fr) Inhibition des metalloproteases matricielles par les acides biaryle oxobutyriques substitues
EP0907632A1 (fr) Inhibition de metalloproteases matricielles par des composes de phenetyle substitues
AU715877B2 (en) Inhibition of matrix metalloproteases by 2-(omega- aroylalkyl)-4-biaryl-oxobutyric acids
US5968795A (en) Biaryl acetylenes as inhibitors of matrix metalloproteases
AU710759B2 (en) Inhibition of matrix metalloproteases by acetylene containing compounds
EP0923529B1 (fr) Derives de l'acide 4-arylbutyrique substitue agissant comme inhibiteurs de la metalloprotease matricielle
US5863915A (en) Substituted 4-arylbutyric acid derivatives as matrix metalloprotease
US5804581A (en) Inhibition of matrix metalloproteases by substituted phenalkyl compounds
JP3417951B2 (ja) マトリックスメタロプロテアーゼ阻害剤としての置換されたオキシ酪酸
US5932763A (en) Inhibition of matrix metalloproteases by 2-(ω-arolalkyl)-4-biaryl-4-oxobutyric acids
WO1997043238A9 (fr) Acides oxobutyriques substitues agissant comme inhibiteurs des metalloproteinases matricielles
US5932577A (en) Substituted oxobutyric acids as matrix metalloprotease inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97196457.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2253870

Country of ref document: CA

Ref document number: 2253870

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997923621

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1997 540979

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997923621

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997923621

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载